Startups take up residence in Alderley Park as AstraZeneca exits; Zogenix surges on pain drug progress;

@FierceBiotech: ICYMI: Top 15 highest paid biopharma R&D chiefs. Special report | Follow @FierceBiotech

@JohnCFierce: The turnaround plan: stay put, target drugs, more deals--John Reed sets out on a long-distance run at Roche's pRED. Feature | Follow @JohnCFierce

@DamianFierce: Updated story on Frazier's $377M new fund with comments from General Partner Jamie Topper. ICYMI yesterday | Follow @DamianFierce

@EmilyMFierce: NIH Feels Multiplying Effects of Government Shutdown. Article from Scientific American | Follow @EmilyMFierce

> Six new startups--including several biotechs--have taken up residence at the new BioHub in Alderley Park. Story

> Zogenix ($ZGNX) shares surged on the news that its troubled pain drug Zohydro may be moving closer to a possible approval. Story

> StemCells ($STEM) has landed regulatory permission to start a study of its stem cell treatment for spinal cord injuries. Report

> KenCord BioTherapeutics may have only $15 million in backing, but it's promising to create 200 new jobs in Charlotte, NC. Story

Medical Device News

@FierceMedDev: Lensar hauls in $87M for laser eye surgery tech. News | Follow @FierceMedDev

@MarkHFierce: FierceDiagnostics has another great crop of stories for you. Check it out | Follow @MarkHFierce

@MichaelGFierce: ICYMI: Oral peptide delivery biz Enteris lands Nordic partnership. More from FierceDrugDelivery | Follow @MichaelGFierce

> Covidien CEO: It's about how, not how much, you spend on R&D. Report

> With Mako set for sale, Wright may be next orthopedic M&A target. Story

> Report: French regulators acted too slowly on PIP breast implant scandal. Item

Pharma News

@FiercePharma: Funnily enough, we publish Top 15 Drug Launch Superstars, and 1000s click thru to last year's Top 10 Launch Disasters. | Follow @FiercePharma

@CarlyHFierce: ICYMI yesterday: Acino agrees to $439M takeover offer from private equity firms. More | Follow @CarlyHFierce

> Lilly warns of 'challenging' bid for 2014 sales goal, thanks to yen, emerging markets. News

> Novartis, Sanofi, Biogen tout new MS drug research. Story

Vaccines News

> NIH expands vaccine clinical trial network. Item

> CDC reports across-the-board rises in flu vaccine uptake. Report

> Researchers highlight knowledge gaps hindering cancer vaccines. Story

> Vaccines spared as Merck takes ax to R&D. More

> Government shutdown forces CDC to halt seasonal flu program. Article

Pharma Manufacturing News

@EricPFierce: Hospira faces more vial problems. FDA and co. says glass strands pose potential health threat. More | Follow @EricPFierce

> Ranbaxy denies FDA issues will lead to layoffs. Item

> SCM offers 'blank canvas' to sterile injectable clients. Story

> FDA threatens drugmaker with ban for not paying user fee. Article

> CML, AAIPharma join forces to create CMC specialist. More

And Finally... Investigators at McMasters University say they have developed a novel tuberculosis vaccine. The vaccine relies on a modified cold virus and was developed in the lab of Zhou Xing. Release

Suggested Articles

Q32 Bio raised $60 million to push its lead antibody through the clinic and bolster its pipeline and the technology behind it.

Sanofi is teaming up with Merck while AstraZeneca taps Arcus as the future of cancer work is very much made together.

The action follows the FDA’s decision to reject a filing for approval of the JAK1 inhibitor in rheumatoid arthritis due to toxicity concerns.